PharmaSGP Holding SE
PSG
ISIN DE000A2P4LJ5 / Valor 55294050
PharmaSGP Holding SE
UMushroom community rating:
About company
PharmaSGP Holding SE is a consumer health company specializing in natural non-prescription pharmaceuticals and healthcare products, primarily sold through pharmacies. The company's core brands focus on chronic indications such as pain and age-related ailments, with leading products like RubaXX® and Restaxil® for pain relief, as well as DESEO® and Neradin® for men's health. Recently, PharmaSGP expanded its portfolio with the acquisition of OTC brands like Baldriparan®, Formigran®, Spalt®, and Kamol®, further solidifying its position in the pain therapy and sleep disorder categories. With a strategic focus on expanding its "Health Brands" category and entering new markets in Europe, PharmaSGP aims to continue its growth trajectory through both organic expansion and strategic acquisitions.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (20.08.2024):
Revenue Growth
PharmaSGP Holding SE reported a significant increase in revenue for Q1 2024, reaching €30.2 million. This represents a 25.8% growth compared to the same quarter in the previous year, showcasing the company's strong market performance and successful expansion strategies.
Adjusted EBITDA
In Q1 2024, PharmaSGP Holding SE achieved an adjusted EBITDA of €8.9 million. This marks an improvement from the €7.0 million reported in Q1 2023, reflecting the company's efficient cost management and scalable business model.
Adjusted EBIT
PharmaSGP Holding SE's adjusted EBIT for Q1 2024 was €6.5 million, up from €4.7 million in Q1 2023. The increase in EBIT indicates enhanced operational efficiency and profitability within the company.
Equity Ratio
The equity ratio of PharmaSGP Holding SE improved to 31.7% in Q1 2024, compared to 25.0% in Q1 2023. This improvement in the equity ratio highlights the company's strengthened financial position and stability.
Balance Sheet Total
PharmaSGP Holding SE's balance sheet total reached €140.9 million in Q1 2024, up from €133.6 million in Q1 2023. The increase in the balance sheet total reflects the company's growth and successful financial management strategies.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
283 M
Market cap (USD)
4,311
Daily traded volume (Shares)
21.4 / 20.8
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
